Filter

Refine by date

—

Refine by collections

  • Print
  • Save

Search Results

You are looking at 1 - 10 of 18 items for :

  • "Selpercatinib" x
Clear All
Marine Sitbon Pharmacy Department, Hospital Saint-Louis APHP, Paris, France

Search for other papers by Marine Sitbon in
Google Scholar
PubMed Close
,
Porhuoy Chou Endocrine Oncology Department, Saint-Louis Hospital (AP-HP), Université Paris Cité, Paris, France

Search for other papers by Porhuoy Chou in
Google Scholar
PubMed Close
,
Seydou Bengaly Endocrine Oncology Department, Saint-Louis Hospital (AP-HP), Université Paris Cité, Paris, France

Search for other papers by Seydou Bengaly in
Google Scholar
PubMed Close
,
Brigitte Poirot Department of Molecular Oncology, Saint-Louis Hospital (AP-HP), Université Paris Cité INSERM U 944, CNRS UMR 7212, Paris, France

Search for other papers by Brigitte Poirot in
Google Scholar
PubMed Close
,
Marie Laloi-Michelin Department of Internal Medicine, Hospital Lariboisière APHP, Paris, France

Search for other papers by Marie Laloi-Michelin in
Google Scholar
PubMed Close
,
Laure Deville Pharmacy Department, Hospital Saint-Louis APHP, Paris, France

Search for other papers by Laure Deville in
Google Scholar
PubMed Close
,
Atanas Pachev Radiology Department, Saint-Louis Hospital (AP-HP), Université Paris Cité, Paris, France

Search for other papers by Atanas Pachev in
Google Scholar
PubMed Close
,
Ahouefa Kowo-Bille Endocrine Oncology Department, Saint-Louis Hospital (AP-HP), Université Paris Cité, Paris, France

Search for other papers by Ahouefa Kowo-Bille in
Google Scholar
PubMed Close
,
Clement Dumont Medical Oncology Department, Saint-Louis Hospital (AP-HP), Université Paris Cité, Paris, France

Search for other papers by Clement Dumont in
Google Scholar
PubMed Close
, and
Cécile N Chougnet Endocrine Oncology Department, Saint-Louis Hospital (AP-HP), Université Paris Cité, Paris, France

Search for other papers by Cécile N Chougnet in
Google Scholar
PubMed Close

. Novel insights Efficacy of selpercatinib in MTC-associated paraneoplastic Cushing’s syndrome. Selpercatinib elicits a rapid and long-lasting response in RET-mutated MTC with bone metastases in the first line. Introduction The

Article Type:
Case Report
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-22-0032
Volume/Issue:
Volume 11: Issue 6
Open access
Stéphane Bardet Department of Nuclear Medicine and Thyroid Unit, Centre François Baclesse, Caen, France

Search for other papers by Stéphane Bardet in
Google Scholar
PubMed Close
,
Renaud Ciappuccini Department of Nuclear Medicine and Thyroid Unit, Centre François Baclesse, Caen, France

Search for other papers by Renaud Ciappuccini in
Google Scholar
PubMed Close
,
Livia Lamartina Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Villejuif, France

Search for other papers by Livia Lamartina in
Google Scholar
PubMed Close
, and
Sophie Leboulleux Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Villejuif, France

Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed Close

Established facts Serum CT and CEA are valuable tumour markers in patients with MTC, which most often decrease in parallel after the initiation of efficient treatment. Selpercatinib (LOXO-292) is a highly selective RET kinase

Article Type:
Case Report
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-21-0104
Volume/Issue:
Volume 11: Issue 2
Open access
Carla Gambale C Gambale, Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy

Search for other papers by Carla Gambale in
Google Scholar
PubMed Close
,
Alessandro Prete A Prete, Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy

Search for other papers by Alessandro Prete in
Google Scholar
PubMed Close
,
Chiara Romei C Romei, Department of Diagnostic Imaging, Unit of Radiology 2, Pisa University Hospital, Pisa, Italy

Search for other papers by Chiara Romei in
Google Scholar
PubMed Close
,
Alessandro Celi A Celi, Department of Surgery, Medicine, Molecular Biology and Critical Care, Respiratory Pathophysiology Unit, Pisa University Hospital, Pisa, Italy

Search for other papers by Alessandro Celi in
Google Scholar
PubMed Close
,
Rossella Elisei R Elisei, Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy

Search for other papers by Rossella Elisei in
Google Scholar
PubMed Close
, and
Antonio Matrone A Matrone, Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, 56124, Italy

Search for other papers by Antonio Matrone in
Google Scholar
PubMed Close

Highly selective RET inhibitor selpercatinib has demonstrated notable efficacy in advanced/progressive RET-mutant medullary thyroid cancer (MTC) patients. However, despite a more tolerable toxicity profile than multikinase inhibitors, peculiar adverse events (AEs) have been described. Obliterative bronchiolitis (OB) is a respiratory disease characterized by inflammation and fibrosis in small conducting airways. We evaluated a 70 years-old man with advanced RET-mutant MTC who developed OB during treatment with selpercatinib. Radiological features of OB occurred early and persisted during selpercatinib treatment, with a waxing and waning pattern. Notably, a partial response of MTC was achieved during the treatment and selpercatinib was never reduced or interrupted. The almost complete absence of symptoms and the fluctuating trend, without specific treatment for OB, suggested that it is necessary to carefully evaluate the risks mediated by this AE with the risks of modifying or discontinuing the anti-cancer therapy.

Article Type:
Case Report
DOI:
https://doi.org/10.1530/ETJ-24-0189
Volume/Issue:
Accepted Manuscripts
Open access
Carla Colombo Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Carla Colombo in
Google Scholar
PubMed Close
,
Daniele Ceruti Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy

Search for other papers by Daniele Ceruti in
Google Scholar
PubMed Close
,
Massimiliano Succi Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy

Search for other papers by Massimiliano Succi in
Google Scholar
PubMed Close
,
Simone De Leo Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy

Search for other papers by Simone De Leo in
Google Scholar
PubMed Close
,
Matteo Trevisan Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy
Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy

Search for other papers by Matteo Trevisan in
Google Scholar
PubMed Close
,
Claudia Moneta Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy

Search for other papers by Claudia Moneta in
Google Scholar
PubMed Close
, and
Laura Fugazzola Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Laura Fugazzola in
Google Scholar
PubMed Close

Europe, the multikinase inhibitors sorafenib, lenvatinib (LEN) and cabozantinib have been approved for RAI-R DTC, vandetanib (VAN) and cabozantinib for MTC, and the gene-targeted selpercatinib (SELP) and larotrectinib for cancers harbouring rearranged

Article Type:
Research Article
Collections:
Thyroid cancer - basic and translational
DOI:
https://doi.org/10.1530/ETJ-23-0246
Volume/Issue:
Volume 13: Issue 3
Open access
Markus Eszlinger Departments of Oncology, Pathology and Laboratory Medicine, Biochemistry and Molecular Biology, and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Heritage Medical Research Building, Calgary, Alberta, Canada
Institute of Pathology, University Hospital Halle (Saale), Halle (Saale), Germany

Search for other papers by Markus Eszlinger in
Google Scholar
PubMed Close
,
Paul Stewardson Department of Medical Science and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Paul Stewardson in
Google Scholar
PubMed Close
,
John B McIntyre Precision Oncology Hub Laboratory, Alberta Health Services, Tom Baker Cancer Centre, Calgary, Alberta, Canada

Search for other papers by John B McIntyre in
Google Scholar
PubMed Close
,
Adrian Box Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Adrian Box in
Google Scholar
PubMed Close
,
Moosa Khalil Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Moosa Khalil in
Google Scholar
PubMed Close
,
Martin Hyrcza Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Martin Hyrcza in
Google Scholar
PubMed Close
,
Konstantin Koro Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Konstantin Koro in
Google Scholar
PubMed Close
,
Dean Ruether Section of Medical Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Dean Ruether in
Google Scholar
PubMed Close
,
Jiahui Wu Department of Medical Science and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada

Search for other papers by Jiahui Wu in
Google Scholar
PubMed Close
, and
Ralf Paschke Departments of Medicine, Oncology, Pathology and Laboratory Medicine, Biochemistry and Molecular Biology, and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Heritage Medical Research Building, Calgary, Alberta, Canada

Search for other papers by Ralf Paschke in
Google Scholar
PubMed Close

metastatic, where surgery would result in severe morbidity, or where no satisfactory alternative therapy is available. The receptor tyrosine kinase (RET) inhibitors, selpercatinib and pralsetinib, were approved by the FDA for advanced or metastatic RET

Article Type:
Research Article
Collections:
Thyroid cancer - basic and translational
DOI:
https://doi.org/10.1530/ETJ-21-0061
Volume/Issue:
Volume 11: Issue 1
Open access
Ségolène Hescot Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France

Search for other papers by Ségolène Hescot in
Google Scholar
PubMed Close
,
Julien Masliah-Planchon Department of Genetics, Institut Curie, Paris, France

Search for other papers by Julien Masliah-Planchon in
Google Scholar
PubMed Close
,
Pauline du Rusquec Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France

Search for other papers by Pauline du Rusquec in
Google Scholar
PubMed Close
,
Célia Dupain Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France

Search for other papers by Célia Dupain in
Google Scholar
PubMed Close
,
Maud Kamal Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France

Search for other papers by Maud Kamal in
Google Scholar
PubMed Close
,
Vincent Servois Department of Radiology, Institut Curie, Paris, France

Search for other papers by Vincent Servois in
Google Scholar
PubMed Close
, and
Ivan Bieche Department of Genetics, Institut Curie, Paris, France

Search for other papers by Ivan Bieche in
Google Scholar
PubMed Close

mutation occurs in codon M918, reported in up to 90% of RET-positive MTC cases ( 2 ). Selpercatinib and pralsetinib, tyrosine-kinase inhibitors with high specificity for RET protein, recently obtained FDA approval for the treatment of lung and thyroid

Article Type:
Case Report
Collections:
Thyroid cancer - basic and translational
DOI:
https://doi.org/10.1530/ETJ-22-0044
Volume/Issue:
Volume 11: Issue 5
Open access
Camille Buffet Department of Thyroid Pathologies and Endocrine Tumors, AP-HP, Pitié-Salpêtrière Hospital, Groupe de Recherche Clinique n°16 Tumeurs Thyroïdiennes, Sorbonne Université, Paris, France
UMR9019, Genome Integrity and Cancers, CNRS, Villejuif, France

Search for other papers by Camille Buffet in
Google Scholar
PubMed Close
,
Sophie Leboulleux Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institut, Villejuif, France

Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed Close
,
Françoise Kraeber-Bodéré Nuclear Medicine Department, Université de Nantes, CHU de Nantes, CNRS, Inserm, CRCINA, Nantes, France
CHU Nantes/ICO, Saint-Herblain, France

Search for other papers by Françoise Kraeber-Bodéré in
Google Scholar
PubMed Close
,
Caroline Bodet-Milin Nuclear Medicine Department, Université de Nantes, CHU de Nantes, CNRS, Inserm, CRCINA, Nantes, France
CHU Nantes/ICO, Saint-Herblain, France

Search for other papers by Caroline Bodet-Milin in
Google Scholar
PubMed Close
,
Laure Cabanes Department of Cardiology, APHP, Cochin Hospital, Paris, France
Université de Paris, Paris, France

Search for other papers by Laure Cabanes in
Google Scholar
PubMed Close
,
Anthony Dohan Radiology Department, Université de Paris, Paris, France
Department of Radiology, AP-HP, Hôpital Cochin, Paris, France

Search for other papers by Anthony Dohan in
Google Scholar
PubMed Close
,
Pascal Leprince Department of Thoracic and Cardiovascular Surgery, Sorbonne Université, AP-HP, Pitié-Salpêtrière Hospital, Paris, France

Search for other papers by Pascal Leprince in
Google Scholar
PubMed Close
,
Martin Schlumberger UMR9019, Genome Integrity and Cancers, CNRS, Villejuif, France
Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institute, Villejuif, France

Search for other papers by Martin Schlumberger in
Google Scholar
PubMed Close
,
Olivier Huillard Université de Paris, Sorbonne Paris Cité, Paris, France
Department of Medical Oncology, AP-HP, Hôpital Cochin, Paris, France

Search for other papers by Olivier Huillard in
Google Scholar
PubMed Close
, and
Lionel Groussin INSERM Unité 1016, CNRS UMR 8104, Institut Cochin, Paris, France
Université de Paris, Paris, France
Department of Endocrinology, AP-HP, Hôpital Cochin, Paris, France

Search for other papers by Lionel Groussin in
Google Scholar
PubMed Close

performed on brain metastases. The patient was included in a phase 1–2 trial evaluating the highly specific RET inhibitor selpercatinib [ 9 ]. Five weeks after selpercatinib initiation, the patient developed a confusional state. The MRI performed 8 days

Article Type:
Case Report
DOI:
https://doi.org/10.1159/000517716
Volume/Issue:
Volume 10: Issue 6
Open access
Jihwan Yoo Department of Neurosurgery, Brain Tumor Center, Gangnam Severance Hospital, Seoul, Republic of Korea
College of Medicine, Yonsei University, Seoul, Republic of Korea

Search for other papers by Jihwan Yoo in
Google Scholar
PubMed Close
,
Hee Jun Kim Department of Surgery, CHA Ilsan Medical Center, Cha University School of Medicine, Goyang-si, Republic of Korea

Search for other papers by Hee Jun Kim in
Google Scholar
PubMed Close
,
Seok Mo Kim Department of Surgery, Thyroid Cancer Center, Gangnam Severance Hospital, Institute of Refractory Thyroid Cancer, Yonsei University College of Medicine, Seoul, Republic of Korea

Search for other papers by Seok Mo Kim in
Google Scholar
PubMed Close
, and
Hun Ho Park Department of Neurosurgery, Brain Tumor Center, Gangnam Severance Hospital, Seoul, Republic of Korea

Search for other papers by Hun Ho Park in
Google Scholar
PubMed Close

( 26 ). In the open-label, phase 1/2 clinical trial, 20 RET-fusion-positive thyroid cancer patients were included, showing an overall response rate (ORR) of 89% ( 30 ). Wirth et al . reported a comparable response rate in a selpercatinib study, with an

Article Type:
Research Article
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-22-0087
Volume/Issue:
Volume 11: Issue 5
Open access
Pepijn van Houten Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Pepijn van Houten in
Google Scholar
PubMed Close
,
James Nagarajah Roentgeninstitut Duesseldorf, Duesseldorf, Germany
Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by James Nagarajah in
Google Scholar
PubMed Close
,
Janneke E W Walraven Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Janneke E W Walraven in
Google Scholar
PubMed Close
,
Martin Jaeger Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Martin Jaeger in
Google Scholar
PubMed Close
,
Adriana C H van Engen-van Grunsven Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Adriana C H van Engen-van Grunsven in
Google Scholar
PubMed Close
,
Johannes W Smit Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Johannes W Smit in
Google Scholar
PubMed Close
, and
Romana T Netea-Maier Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands
Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

Search for other papers by Romana T Netea-Maier in
Google Scholar
PubMed Close

inhibitors dabrafenib and vemurafenib, MEK inhibitors trametinib and selumetinib, RET inhibitor selpercatinib, and TRK inhibitor larotrectinib) regarding the enhancement of RAI uptake in RAI-refractory NMTC patients. Although these results are promising

Article Type:
Research Article
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-24-0153
Volume/Issue:
Volume 13: Issue 4
Open access
Abdul Rehman Syed University of Calgary, Calgary, Alberta, Canada

Search for other papers by Abdul Rehman Syed in
Google Scholar
PubMed Close
,
Aakash Gorana Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada

Search for other papers by Aakash Gorana in
Google Scholar
PubMed Close
,
Erik Nohr Alberta Precision Laboratories, Molecular Pathology Program, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

Search for other papers by Erik Nohr in
Google Scholar
PubMed Close
,
Xiaoli-Kat Yuan Precision Oncology Hub Laboratory, Tom Baker Cancer Centre, Calgary, Alberta, Canada

Search for other papers by Xiaoli-Kat Yuan in
Google Scholar
PubMed Close
,
Parthiv Amin MASc Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary Alberta, Canada

Search for other papers by Parthiv Amin MASc in
Google Scholar
PubMed Close
,
Sana Ghaznavi Arnie Charbonneau Cancer Institute, Department of Medicine, Section of Endocrinology, University of Calgary, Calgary, Alberta, Canada

Search for other papers by Sana Ghaznavi in
Google Scholar
PubMed Close
,
Debbie Lamb Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada

Search for other papers by Debbie Lamb in
Google Scholar
PubMed Close
,
John McIntyre Precision Oncology Hub Laboratory, Tom Baker Cancer Centre, Calgary, Alberta, Canada

Search for other papers by John McIntyre in
Google Scholar
PubMed Close
,
Markus Eszlinger Department of Oncology, Cumming School of Medicine, and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada

Search for other papers by Markus Eszlinger in
Google Scholar
PubMed Close
, and
Ralf Paschke Departments of Medicine, Section of Endocrinology, Oncology, Pathology and Laboratory Medicine, Biochemistry and Molecular Biology and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

Search for other papers by Ralf Paschke in
Google Scholar
PubMed Close

). Recently, this strategy was extended to rarer oncogenic fusion genes like RET and NTRK1/2/3 rearrangements using the RET inhibitor selpercatinib and the NTRK inhibitor larotrectinib ( 6 , 8 , 9 ). The first instance of RAI uptake restoration leading

Article Type:
Research Article
Collections:
Thyroid cancer - basic and translational
DOI:
https://doi.org/10.1530/ETJ-23-0227
Volume/Issue:
Volume 13: Issue 3
Open access